Entrada Therapeutics, Inc. (NASDAQ:TRDA) is MPM Asset Management LLC’s Largest Position

MPM Asset Management LLC lessened its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,381,062 shares of the company’s stock after selling 44,722 shares during the period. Entrada Therapeutics makes up 60.9% of MPM Asset Management LLC’s holdings, making the stock its biggest position. MPM Asset Management LLC owned approximately 0.12% of Entrada Therapeutics worth $75,749,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Barclays PLC increased its stake in Entrada Therapeutics by 210.6% during the third quarter. Barclays PLC now owns 45,110 shares of the company’s stock worth $720,000 after acquiring an additional 30,585 shares during the last quarter. SG Americas Securities LLC lifted its stake in Entrada Therapeutics by 44.0% during the fourth quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock worth $243,000 after purchasing an additional 4,291 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Entrada Therapeutics in the 4th quarter valued at about $137,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Entrada Therapeutics by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock valued at $3,408,000 after acquiring an additional 11,143 shares during the period. Finally, AlphaQuest LLC purchased a new stake in shares of Entrada Therapeutics in the fourth quarter valued at about $70,000. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $8.70 on Wednesday. Entrada Therapeutics, Inc. has a 1 year low of $7.10 and a 1 year high of $21.79. The firm has a market cap of $330.19 million, a PE ratio of 5.47 and a beta of 0.04. The firm’s 50-day simple moving average is $9.13 and its 200-day simple moving average is $13.65.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.36. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. On average, equities analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 31st.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.